Physician Quick Search
By Name:
By Specialty:
314-TOP-DOCS
When you need to get the name of one of the nation’s top doctors as close to home as St. Louis, just call 314-TOP-DOCS (314-867-3627) or toll free 1-866-867-3627. This is the physician referral and health information line from Barnes-Jewish Hospital.
Your Healthy Update

Like us on Facebook
Text Size: S M L
Search

Internal Medicine / Cardiovascular-Cardiac Cath

John M. Lasala, MD, PhD, FACC

Current Position
Associate Professor, Medicine
Director, Interventional Cardiology
Medical Director, Cardiac Catheterization Lab


Specialty Areas
Cardiac Catheterization
Cardiology
Interventional Cardiology

Patients Seen At
Cardiac Catheterization Laboratory
One Barnes-Jewish Hospital
St. Louis, MO  63110
314-362-2284
View Driving Directions

Areas of Clinical Interest
Interventional cardiology, cardiac catheterizations, coronary artery disease, circulation, angioplasty, percutaneous transluminal coronary angioplasty (PTCA), myocardial infarction, coronary-artery stenting, Wolff-Parkinson White syndrome, ascending and descending aortic dissections, aortic aneurysms

Board Certification
Cardiology -- Certified
Internal Medicine -- Certified

Patients must be referred by a physician.

Medical Education
B.A.: Drew University, Madison, New Jersey, 1975
Ph.D.: St. Louis University, St. Louis, Missouri, 1979
Fellowship: Postdoctoral Anatomy and Neurobiology, Washington University School of Medicine, St. Louis, Missouri, 1979
Medical Degree: University Of Connecticut, Storrs, Connecticut, 1983
Residency: Internal Medicine, Barnes Hospital, Washington University School of Medicine, St. Louis, Missouri, 1986
Fellowship: Postdoctoral Cardiology, Yale University School of Medicine, New Haven, Connecticut, 1989
Fellowship: Intervential Cardiology, Yale University School of Medicine, New Haven, Connecticut, 1990
Hospital Affiliations
Barnes-Jewish Hospital

Honors and Awards
Listed in Best Doctors in America, 2003-2013 (Best Doctors, Inc.)
Hugh McCulloch Award Recipient, 2011

Disclosure of Financial Interests with Industry
Washington University and its physicians are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians work collaboratively with pharmaceutical or medical device companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our faculty physicians are paid by these commercial companies to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this web site, physicians earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.

Dr. John M. Lasala reported the following earned financial interests during calendar year 2013. Move your mouse over a header for more info.
Company
Royalties
Royalties: When a faculty member invents or conceives a new or improved process or product, the company that manufactures the product will make royalty payments to the faculty member. Royalty payments usually are a small percentage of the company’s revenue related to that product.
Equity
Equity: Equity is an ownership interest in a company. Faculty members may be paid for their service to a company in stock or the option to obtain stock.
Consulting &
Advisory Boards
Consulting and Advisory Boards: Faculty may be paid to provide expertise to a company by being their consultant, or by serving on an advisory board.
Speaker Fees
Speaker Fees: Companies may pay faculty to speak to professional audiences about their products.
Eli Lilly    $25,001-$50,000 
Abiomed  Yes $1,000-$10,000 $50,001-$100,000 
To learn more about Washington University's policies on collaborations with industry, click here.

Editorial Responsibilities
Circulation: Cardiovascular Interventions
Catheterization & Cardiovascular Intervention
American Journal of Cardiology
American Heart Journal
Journal of Thoracic Surgery
Journal of Hypertension
Video Journal of Cardiology
The Interventional Fellows Institute
Journal of Invasive Cardiology
Interventional Cardiology Test Committee for American Board of Internal Medicine

Selected or Recent Journal Articles
Depta JP, Patel Y, Patel JS, Novak E, Yeung M, Zajarias A, Kurz HI, Lasala JM, Bach RG, Singh J. Long-term clinical outcomes with the use of a modified provisional jailed-balloon stenting technique for the treatment of nonleft main coronary bifurcation lesions. Catheter Cardiovasc Interv. 2013 Nov 1;82(5):E637-46.

Vasquez AF, Lasala JM. Atrial septal defect closure. Cardiol Clin. 2013 Aug;31(3):385-400.

D'Ascenzo F, Bollati M, Clementi F, Castagno D, Lagerqvist B, de la Torre Hernandez JM, ten Berg JM, Brodie BR, Urban P, Jensen LO, Sardi G, Waksman R, Lasala JM, Schulz S, Stone GW, Airoldi F, Colombo A, Lemesle G, Applegate RJ, Buonamici P, Kirtane AJ, Undas A, Sheiban I, Gaita F, Sangiorgi G, Modena MG, Frati G, Biondi-Zoccai G. Incidence and predictors of coronary stent thrombosis: evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. Int J Cardiol. 2013 Jul 31;167(2):575-84.

Patel Y, Depta JP, Patel JS, Masrani SK, Novak E, Zajarias A, Kurz HI, Lasala JM, Bach RG, Singh J. Impact of intravascular ultrasound on the long-term clinical outcomes in the treatment of coronary ostial lesions. Catheter Cardiovasc Interv. 2013 Jun 1.

Singh J, Patel Y, Depta JP, Mathews SJ, Cyrus T, Zajarias A, Kurz HI, Lasala JM, Bach RG. A modified provisional stenting approach to coronary bifurcation lesions: clinical application of the "jailed-balloon technique". J Interv Cardiol. 2012 Jun;25(3):289-96.

Patel Y, Depta JP, Novak E, Yeung M, Lavine K, Banerjee S, Lin CH, Zajarias A, Kurz HI, Lasala JM, Bach RG, Singh J. Long-term outcomes with use of intravascular ultrasound for the treatment of coronary bifurcation lesions. Am J Cardiol. 2012 Apr 1;109(7):960-5.

Reynolds MR, Magnuson EA, Wang K, Lei Y, Vilain K, Walczak J, Kodali SK, Lasala JM, O'Neill WW, Davidson CJ, Smith CR, Leon MB, Cohen DJ; PARTNER Investigators. Cost-effectiveness of transcatheter aortic valve replacement compared with standard care among inoperable patients with severe aortic stenosis: results from the placement of aortic transcatheter valves (PARTNER) trial (Cohort B). Circulation. 2012 Mar 6;125(9):1102-9.

Brilakis ES, Lasala JM, Cox DA, Bowman TS, Starzyk RM, Dawkins KD. Two-Year outcomes after utilization of the TAXUS paclitaxel-eluting stent in bifurcations and multivessel stenting in the ARRIVE registries. J Interv Cardiol. 2011 Aug;24(4):342-50.

Lee MS, Yang T, Lasala JM, Cox DA, Bowman TS, Starzyk RM, Dawkins KD. Two-year clinical outcomes of paclitaxel-eluting stents for in-stent restenosis in patients from the ARRIVE programme. EuroIntervention. 2011 Jul;7(3):314-22.

Lin CH, Balzer DT, Lasala JM. Defect closure in the lipomatous hypertrophied atrial septum with the Amplatzer muscular ventricular septal defect closure device: a case series. Catheter Cardiovasc Interv. 2011 Jul 1;78(1):102-7.

Huang PH, Yeung M, Lasala JM, Cox DA, Bowman TS, Starzyk RM, Dawkins KD. Two-year clinical outcomes with paclitaxel-eluting coronary stents in patients with chronic total occlusions: analysis from the TAXUS ARRIVE program. J Interv Cardiol. 2011 Jun;24(3):232-40.

Baran KW, Lasala JM, Cox DA, Mascioli SR, Song A, Deshpande MC, Jacoski MV, Dawkins KD; ARRIVE Investigators. A clinical risk score for the prediction of very late stent thrombosis in drug eluting stent patients. EuroIntervention. 2011 Mar;6(8):949-54.

Mikhail GW, Gerber RT, Cox DA, Ellis SG, Lasala JM, Ormiston JA, Stone GW, Turco MA, Joshi AA, Baim DS, Colombo A. Influence of sex on long-term outcomes after percutaneous coronary intervention with the paclitaxel-eluting coronary stent: results of the "TAXUS Woman" analysis. JACC Cardiovasc Interv. 2010 Dec;3(12):1250-9.

Huang PH, Zajarias A, Lasala JM. Bleeding avoidance strategies and percutaneous coronary intervention. JAMA. 2010 Sep 8;304(10):1068; author reply 1068-9.

Brilakis ES, Lasala JM, Cox DA, Berger PB, Bowman TS, Starzyk RM, Dawkins KD. Outcomes after implantation of the TAXUS paclitaxel-eluting stent in saphenous vein graft lesions: results from the ARRIVE (TAXUS Peri-Approval Registry: A Multicenter Safety Surveillance) program. JACC Cardiovasc Interv. 2010 Jul;3(7):742-50

For more articles and abstracts, take this off-site link to the National Library of Medicine Pub Med page for Dr. John Lasala.



Washington University Physicians are the medical staff of  Barnes-Jewish Hospital and Children's Hospital - St. Louis Employment   About Us   Top Stories   For Your Protection      Site Map
Copyright 2014 Washington University School of Medicine
Copyright 2014 Washington University School of Medicine